SARS-CoV-2 gains entry to human cells through its spike (S) protein binding to angiotensin-
converting enzyme 2 (ACE2). Therefore, the receptor binding domain (RBD) of the S protein …

Immediately from the outset of the COVID-19 pandemic, researchers from diverse
biomedical and biological disciplines have united to study the novel pandemic virus, SARS …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …

Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …

The emerging new lineages of severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) have marked a new phase of coronavirus disease 2019 (COVID-19). Understanding …

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …

Infection with SARS‐CoV‐2 elicits robust antibody responses in some patients, with a
majority of the response directed at the receptor binding domain (RBD) of the spike surface …

Understanding the mechanism for antibody neutralization of SARS-CoV-2 is critical for the
development of effective therapeutics and vaccines. We recently isolated a large number of …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …

Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …